Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
Go back to Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study| Pfizer Inc. (NYSE: PFE) | Delayed: 28.03 -0.21 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.24 | 52 Week High | $37.39 | |||
| Open | $28.00 | 52 Week Low | $28.25 | |||
| Day High | $28.16 | P/E | 16.99 | |||
| Day Low | $27.65 | EPS | $1.65 | |||
| Volume | 18,280,537 | |||||
